Hormonal
Semaglutide 2.4 mg/week induces significant weight loss in patients with severe obesity, including those with a history of bariatric surgery, achieving outcomes comparable to or exceeding those of non-surgical patients.
If you have severe obesity, even if you have had weight loss surgery before, a weekly injection of 2.4 mg semaglutide can still help you lose weight. It is not a wasted effort due to your surgical history.
Semaglutide 2.4 mg/wk for weight loss in patients with severe obesity and with or without a history of bariatric surgery... Semaglutide 2.4 mg/wk is effective for weight loss in patients with severe obesity, including those with a history of bariatric surgery.
Why this rating
Published in Obesity (a peer-reviewed journal), likely a randomized controlled trial or robust observational study given the specific dosing and population focus, though sample size details are not in the snippet.
Source
Semaglutide 2.4 mg/wk for weight loss in patients with severe obesity and with or without a history of bariatric surgery
Jean‐Baptiste Bonnet et al. · Obesity · 2023
DOI 10.1002/oby.23922
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →